Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity

Divya Chennamadhavuni, Noemi Alejandra Saavedra-Avila, Leandro J. Carreño, Matthew J. Guberman-Pfeffer, Pooja Arora, Tang Yongqing, Hui Fern Koay, Dale I. Godfrey, Santosh Keshipeddy, Stewart K. Richardson, Srinivasan Sundararaj, Jae Ho Lo, Xiangshu Wen, José A. Gascón, Weiming Yuan, Jamie Rossjohn, Jérôme Le Nours, Steven A. Porcelli, Amy R. Howell

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Glycosylceramides that activate CD1d-restricted invariant natural killer T (iNKT) cells have potential therapeutic applications for augmenting immune responses against cancer and infections. Previous studies using mouse models identified sphinganine variants of α-galactosylceramide as promising iNKT cell activators that stimulate cytokine responses with a strongly proinflammatory bias. However, the activities of sphinganine variants in mice have generally not translated well to studies of human iNKT cell responses. Here, we show that strongly proinflammatory and anti-tumor iNKT cell responses were achieved in mice by a variant of α-galactosylceramide that combines a sphinganine base with a hydrocinnamoyl ester on C6″ of the sugar. Importantly, the activities observed with this variant were largely preserved for human iNKT cell responses. Structural and in silico modeling studies provided a mechanistic basis for these findings and suggested basic principles for capturing useful properties of sphinganine analogs of synthetic iNKT cell activators in the design of immunotherapeutic agents. Chennamadhavuni et al. synthesized an improved activating ligand for iNKT cells by combining carbohydrate and sphingoid base modifications in an α-galactosyl ceramide. Biological and structural studies provide insight into the mechanisms responsible for improved activity and suggest approaches for further optimization of ligand design.

Original languageEnglish (US)
Pages (from-to)571-584.e8
JournalCell Chemical Biology
Volume25
Issue number5
DOIs
StatePublished - May 17 2018

Fingerprint

Galactosylceramides
Natural Killer T-Cells
T-cells
Tumors
Immunity
Chemical activation
Neoplasms
Ligands
Sugars
Computer Simulation
Esters
Carbohydrates
Cytokines
safingol
Infection

Keywords

  • cancer immunotherapy
  • CD1d
  • galactosylceramide
  • iNKT cells
  • KRN7000
  • tumor immunity
  • α-GalCer

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Chennamadhavuni, D., Saavedra-Avila, N. A., Carreño, L. J., Guberman-Pfeffer, M. J., Arora, P., Yongqing, T., ... Howell, A. R. (2018). Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity. Cell Chemical Biology, 25(5), 571-584.e8. https://doi.org/10.1016/j.chembiol.2018.02.009

Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity. / Chennamadhavuni, Divya; Saavedra-Avila, Noemi Alejandra; Carreño, Leandro J.; Guberman-Pfeffer, Matthew J.; Arora, Pooja; Yongqing, Tang; Koay, Hui Fern; Godfrey, Dale I.; Keshipeddy, Santosh; Richardson, Stewart K.; Sundararaj, Srinivasan; Lo, Jae Ho; Wen, Xiangshu; Gascón, José A.; Yuan, Weiming; Rossjohn, Jamie; Le Nours, Jérôme; Porcelli, Steven A.; Howell, Amy R.

In: Cell Chemical Biology, Vol. 25, No. 5, 17.05.2018, p. 571-584.e8.

Research output: Contribution to journalArticle

Chennamadhavuni, D, Saavedra-Avila, NA, Carreño, LJ, Guberman-Pfeffer, MJ, Arora, P, Yongqing, T, Koay, HF, Godfrey, DI, Keshipeddy, S, Richardson, SK, Sundararaj, S, Lo, JH, Wen, X, Gascón, JA, Yuan, W, Rossjohn, J, Le Nours, J, Porcelli, SA & Howell, AR 2018, 'Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity', Cell Chemical Biology, vol. 25, no. 5, pp. 571-584.e8. https://doi.org/10.1016/j.chembiol.2018.02.009
Chennamadhavuni, Divya ; Saavedra-Avila, Noemi Alejandra ; Carreño, Leandro J. ; Guberman-Pfeffer, Matthew J. ; Arora, Pooja ; Yongqing, Tang ; Koay, Hui Fern ; Godfrey, Dale I. ; Keshipeddy, Santosh ; Richardson, Stewart K. ; Sundararaj, Srinivasan ; Lo, Jae Ho ; Wen, Xiangshu ; Gascón, José A. ; Yuan, Weiming ; Rossjohn, Jamie ; Le Nours, Jérôme ; Porcelli, Steven A. ; Howell, Amy R. / Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity. In: Cell Chemical Biology. 2018 ; Vol. 25, No. 5. pp. 571-584.e8.
@article{cc1172670a4d4f1dbafc9b409191e6fb,
title = "Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity",
abstract = "Glycosylceramides that activate CD1d-restricted invariant natural killer T (iNKT) cells have potential therapeutic applications for augmenting immune responses against cancer and infections. Previous studies using mouse models identified sphinganine variants of α-galactosylceramide as promising iNKT cell activators that stimulate cytokine responses with a strongly proinflammatory bias. However, the activities of sphinganine variants in mice have generally not translated well to studies of human iNKT cell responses. Here, we show that strongly proinflammatory and anti-tumor iNKT cell responses were achieved in mice by a variant of α-galactosylceramide that combines a sphinganine base with a hydrocinnamoyl ester on C6″ of the sugar. Importantly, the activities observed with this variant were largely preserved for human iNKT cell responses. Structural and in silico modeling studies provided a mechanistic basis for these findings and suggested basic principles for capturing useful properties of sphinganine analogs of synthetic iNKT cell activators in the design of immunotherapeutic agents. Chennamadhavuni et al. synthesized an improved activating ligand for iNKT cells by combining carbohydrate and sphingoid base modifications in an α-galactosyl ceramide. Biological and structural studies provide insight into the mechanisms responsible for improved activity and suggest approaches for further optimization of ligand design.",
keywords = "cancer immunotherapy, CD1d, galactosylceramide, iNKT cells, KRN7000, tumor immunity, α-GalCer",
author = "Divya Chennamadhavuni and Saavedra-Avila, {Noemi Alejandra} and Carre{\~n}o, {Leandro J.} and Guberman-Pfeffer, {Matthew J.} and Pooja Arora and Tang Yongqing and Koay, {Hui Fern} and Godfrey, {Dale I.} and Santosh Keshipeddy and Richardson, {Stewart K.} and Srinivasan Sundararaj and Lo, {Jae Ho} and Xiangshu Wen and Gasc{\'o}n, {Jos{\'e} A.} and Weiming Yuan and Jamie Rossjohn and {Le Nours}, J{\'e}r{\^o}me and Porcelli, {Steven A.} and Howell, {Amy R.}",
year = "2018",
month = "5",
day = "17",
doi = "10.1016/j.chembiol.2018.02.009",
language = "English (US)",
volume = "25",
pages = "571--584.e8",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity

AU - Chennamadhavuni, Divya

AU - Saavedra-Avila, Noemi Alejandra

AU - Carreño, Leandro J.

AU - Guberman-Pfeffer, Matthew J.

AU - Arora, Pooja

AU - Yongqing, Tang

AU - Koay, Hui Fern

AU - Godfrey, Dale I.

AU - Keshipeddy, Santosh

AU - Richardson, Stewart K.

AU - Sundararaj, Srinivasan

AU - Lo, Jae Ho

AU - Wen, Xiangshu

AU - Gascón, José A.

AU - Yuan, Weiming

AU - Rossjohn, Jamie

AU - Le Nours, Jérôme

AU - Porcelli, Steven A.

AU - Howell, Amy R.

PY - 2018/5/17

Y1 - 2018/5/17

N2 - Glycosylceramides that activate CD1d-restricted invariant natural killer T (iNKT) cells have potential therapeutic applications for augmenting immune responses against cancer and infections. Previous studies using mouse models identified sphinganine variants of α-galactosylceramide as promising iNKT cell activators that stimulate cytokine responses with a strongly proinflammatory bias. However, the activities of sphinganine variants in mice have generally not translated well to studies of human iNKT cell responses. Here, we show that strongly proinflammatory and anti-tumor iNKT cell responses were achieved in mice by a variant of α-galactosylceramide that combines a sphinganine base with a hydrocinnamoyl ester on C6″ of the sugar. Importantly, the activities observed with this variant were largely preserved for human iNKT cell responses. Structural and in silico modeling studies provided a mechanistic basis for these findings and suggested basic principles for capturing useful properties of sphinganine analogs of synthetic iNKT cell activators in the design of immunotherapeutic agents. Chennamadhavuni et al. synthesized an improved activating ligand for iNKT cells by combining carbohydrate and sphingoid base modifications in an α-galactosyl ceramide. Biological and structural studies provide insight into the mechanisms responsible for improved activity and suggest approaches for further optimization of ligand design.

AB - Glycosylceramides that activate CD1d-restricted invariant natural killer T (iNKT) cells have potential therapeutic applications for augmenting immune responses against cancer and infections. Previous studies using mouse models identified sphinganine variants of α-galactosylceramide as promising iNKT cell activators that stimulate cytokine responses with a strongly proinflammatory bias. However, the activities of sphinganine variants in mice have generally not translated well to studies of human iNKT cell responses. Here, we show that strongly proinflammatory and anti-tumor iNKT cell responses were achieved in mice by a variant of α-galactosylceramide that combines a sphinganine base with a hydrocinnamoyl ester on C6″ of the sugar. Importantly, the activities observed with this variant were largely preserved for human iNKT cell responses. Structural and in silico modeling studies provided a mechanistic basis for these findings and suggested basic principles for capturing useful properties of sphinganine analogs of synthetic iNKT cell activators in the design of immunotherapeutic agents. Chennamadhavuni et al. synthesized an improved activating ligand for iNKT cells by combining carbohydrate and sphingoid base modifications in an α-galactosyl ceramide. Biological and structural studies provide insight into the mechanisms responsible for improved activity and suggest approaches for further optimization of ligand design.

KW - cancer immunotherapy

KW - CD1d

KW - galactosylceramide

KW - iNKT cells

KW - KRN7000

KW - tumor immunity

KW - α-GalCer

UR - http://www.scopus.com/inward/record.url?scp=85047113652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047113652&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2018.02.009

DO - 10.1016/j.chembiol.2018.02.009

M3 - Article

VL - 25

SP - 571-584.e8

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 5

ER -